The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Enhertu (trastuzumab deruxtecan)
Australian Public Assessment Report
Device/Product Name
Enhertu
Active ingredients
Trastuzumab deruxtecan
AusPAR Date
Published
Sponsor
Submission Number
Type C- PM-2022-02867-1-4
Submission Type
Extension of indications
Decision
Approved